Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Dina Caceres
    RCphone +1 (305) 2430819

    IRB: 20170529

    SDG: Precision Medicine
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230822 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20230822

    SDG: Precision Medicine
    Disease Site(s):

    Multiple

    Sponsor: NCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

    Eligibility Criteria - NCT05564377 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230834 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20230834

    SDG: Precision Medicine
    Disease Site(s):

    Breast

    Sponsor: NRG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Combination Therapy Choice (ComboMATCH) A ComboMATCH Treatment Trial: Protocol EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense

    Eligibility Criteria - NCT05554354 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230838 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20230838

    SDG: Precision Medicine
    Disease Site(s):

    Multiple

    Sponsor: NRG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Combination Therapy Choice (ComboMATCH) Protocol EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboM

    Eligibility Criteria - NCT05554328 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230841 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20230841

    SDG: Precision Medicine
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Brain and Nervous System,Colon,Esophagus,Kidney,Liver,Lung,Melanoma, skin,Other Endocrine System,Pancreas,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach

    Sponsor: SWOG

    Enrolling Sites:

    ABLEH
    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    EAY191-S3, Phase II Study Of Paclitaxel (Nsc #673089) + Ipatasertib (Nsc #781451) In Taxane-Refractory Participants With Akt-Altered Advanced Non-Breast Solid Tumors (A Combomatch Treatment Trial)

    Eligibility Criteria - NCT05554380 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231032 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20231032

    SDG: Precision Medicine
    Disease Site(s):

    Other Digestive Organ

    Sponsor: NCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS

    Eligibility Criteria - NCT05564403 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230687 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:

    IRB: 20230687

    SDG: Precision Medicine
    Disease Site(s):

    Multiple

    Sponsor: Tango Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

    Eligibility Criteria - NCT05732831 *This information has been extracted from " www.clinicaltrials.gov"